Recommended Topic Related To:

Zemuron

"Potential drug treatments are tested on paper, in laboratories and eventually in thousands of people. But every drug that goes through this cycle “ every drug that FDA approves “ carries some risk. One of the first lines of defense against "...

Zemuron

INDICATIONS

ZEMURON® (rocuronium bromide) Injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

DOSAGE AND ADMINISTRATION

ZEMURON is for intravenous use only. This drug should only be administered by experienced clinicians or trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents. Doses of ZEMURON injection should be individualized and a peripheral nerve stimulator should be used to monitor drug effect, need for additional doses, adequacy of spontaneous recovery or antagonism, and to decrease the complications of overdosage if additional doses are administered.

The dosage information which follows is derived from studies based upon units of drug per unit of body weight. It is intended to serve as an initial guide to clinicians familiar with other neuromuscular blocking agents to acquire experience with ZEMURON.

In patients in whom potentiation of, or resistance to, neuromuscular block is anticipated, a dose adjustment should be considered [see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, and Use In Specific Populations].

Dose for Tracheal Intubation

The recommended initial dose of ZEMURON, regardless of anesthetic technique, is 0.6 mg/kg. Neuromuscular block sufficient for intubation (80% block or greater) is attained in a median (range) time of 1 (0.4-6) minute(s) and most patients have intubation completed within 2 minutes. Maximum blockade is achieved in most patients in less than 3 minutes. This dose may be expected to provide 31 (15-85) minutes of clinical relaxation under opioid/nitrous oxide/oxygen anesthesia. Under halothane, isoflurane, and enflurane anesthesia, some extension of the period of clinical relaxation should be expected [see DRUG INTERACTIONS].

A lower dose of ZEMURON (0.45 mg/kg) may be used. Neuromuscular block sufficient for intubation (80% block or greater) is attained in a median (range) time of 1.3 (0.8-6.2) minute(s), and most patients have intubation completed within 2 minutes. Maximum blockade is achieved in most patients in less than 4 minutes. This dose may be expected to provide 22 (12-31) minutes of clinical relaxation under opioid/nitrous oxide/oxygen anesthesia. Patients receiving this low dose of 0.45 mg/kg who achieve less than 90% block (about 16% of these patients) may have a more rapid time to 25% recovery, 12 to 15 minutes.

A large bolus dose of 0.9 or 1.2 mg/kg can be administered under opioid/nitrous oxide/oxygen anesthesia without adverse effects to the cardiovascular system [see CLINICAL PHARMACOLOGY].

Rapid Sequence Intubation

In appropriately premedicated and adequately anesthetized patients, ZEMURON 0.6 to 1.2 mg/kg will provide excellent or good intubating conditions in most patients in less than 2 minutes [see Clinical Studies].

Maintenance Dosing

Maintenance doses of 0.1, 0.15, and 0.2 mg/kg ZEMURON, administered at 25% recovery of control T1 (defined as 3 twitches of train-of-four), provide a median (range) of 12 (2-31), 17 (6-50), and 24 (7-69) minutes of clinical duration under opioid/nitrous oxide/oxygen anesthesia [see CLINICAL PHARMACOLOGY]. In all cases, dosing should be guided based on the clinical duration following initial dose or prior maintenance dose and not administered until recovery of neuromuscular function is evident. A clinically insignificant cumulation of effect with repetitive maintenance dosing has been observed [see CLINICAL PHARMACOLOGY].

Use by Continuous Infusion

Infusion at an initial rate of 10 to 12 mcg/kg/min of ZEMURON should be initiated only after early evidence of spontaneous recovery from an intubating dose. Due to rapid redistribution [see CLINICAL PHARMACOLOGY] and the associated rapid spontaneous recovery, initiation of the infusion after substantial return of neuromuscular function (more than 10% of control T1) may necessitate additional bolus doses to maintain adequate block for surgery.

Upon reaching the desired level of neuromuscular block, the infusion of ZEMURON must be individualized for each patient. The rate of administration should be adjusted according to the patient's twitch response as monitored with the use of a peripheral nerve stimulator. In clinical trials, infusion rates have ranged from 4 to 16 mcg/kg/min.

Inhalation anesthetics, particularly enflurane and isoflurane, may enhance the neuromuscular blocking action of nondepolarizing muscle relaxants. In the presence of steady-state concentrations of enflurane or isoflurane, it may be necessary to reduce the rate of infusion by 30% to 50%, at 45 to 60 minutes after the intubating dose.

Spontaneous recovery and reversal of neuromuscular blockade following discontinuation of ZEMURON infusion may be expected to proceed at rates comparable to that following comparable total doses administered by repetitive bolus injections [see CLINICAL PHARMACOLOGY].

Infusion solutions of ZEMURON can be prepared by mixing ZEMURON with an appropriate infusion solution such as 5% glucose in water or lactated Ringers [see Preparation for Administration of ZEMURON]. These infusion solutions should be used within 24 hours of mixing. Unused portions of infusion solutions should be discarded.

Infusion rates of ZEMURON can be individualized for each patient using the following tables for 3 different concentrations of ZEMURON solution as guidelines:

Table 1: Infusion Rates Using ZEMURON Injection (0.5 mg/mL)*

Patient Weight Drug Delivery Rate (mcg/kg/min)
4 5 6 7 8 9 10 12 14 16
(kg) (lbs) Infusion Delivery Rate (mL/hr)
10 22 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2
15 33 7.2 9 10.8 12.6 14.4 16.2 18 21.6 25.2 28.8
20 44 9.6 12 14.4 16.8 19.2 21.6 24 28.8 33.6 38.4
25 55 12 15 18 21 24 27 30 36 42 48
35 77 16.8 21 25.2 29.4 33.6 37.8 42 50.4 58.8 67.2
50 110 24 30 36 42 48 54 60 72 84 96
60 132 28.8 36 43.2 50.4 57.6 64.8 72 86.4 100.8 115.2
70 154 33.6 42 50.4 58.8 67.2 75.6 84 100.8 117.6 134.4
80 176 38.4 48 57.6 67.2 76.8 86.4 96 115.2 134.4 153.6
90 198 43.2 54 64.8 75.6 86.4 97.2 108 129.6 151.2 172.8
100 220 48 60 72 84 96 108 120 144 168 192
* 50 mg ZEMURON in 100 mL solution.

Table 2: Infusion Rates Using ZEMURON Injection (1 mg/mL)*

Patient Weight Drug Delivery Rate (mcg/kg/min)
4 5 6 7 8 9 10 12 14 16
(kg) (lbs) Infusion Delivery Rate (mL/hr)
10 22 2.4 3 3.6 4.2 4.8 5.4 6 7.2 8.4 9.6
15 33 3.6 4.5 5.4 6.3 7.2 8.1 9 10.8 12.6 14.4
20 44 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2
25 55 6 7.5 9 10.5 12 13.5 15 18 21 24
35 77 8.4 10.5 12.6 14.7 16.8 18.9 21 25.2 29.4 33.6
50 110 12 15 18 21 24 27 30 36 42 48
60 132 14.4 18 21.6 25.2 28.8 32.4 36 43.2 50.4 57.6
70 154 16.8 21 25.2 29.4 33.6 37.8 42 50.4 58.8 67.2
80 176 19.2 24 28.8 33.6 38.4 43.2 48 57.6 67.2 76.8
90 198 21.6 27 32.4 37.8 43.2 48.6 54 64.8 75.6 86.4
100 220 24 30 36 42 48 54 60 72 84 96
* 100 mg ZEMURON in 100 mL solution.

Table 3: Infusion Rates Using ZEMURON Injection (5 mg/mL)*

Patient Weight Drug Delivery Rate (mcg/kg/min)
4 5 6 7 8 9 10 12 14 16
(kg) (lbs) Infusion Delivery Rate (mL/hr)
10 22 0.5 0.6 0.7 0.8 1 1.1 1.2 1.4 1.7 1.9
15 33 0.7 0.9 1.1 1.3 1.4 1.6 1.8 2.2 2.5 2.9
20 44 1 1.2 1.4 1.7 1.9 2.2 2.4 2.9 3.4 3.8
25 55 1.2 1.5 1.8 2.1 2.4 2.7 3 3.6 4.2 4.8
35 77 1.7 2.1 2.5 2.9 3.4 3.8 4.2 5 5.9 6.7
50 110 2.4 3 3.6 4.2 4.8 5.4 6 7.2 8.4 9.6
60 132 2.9 3.6 4.3 5 5.8 6.5 7.2 8.6 10.1 11.5
70 154 3.4 4.2 5 5.9 6.7 7.6 8.4 10.1 11.8 13.4
80 176 3.8 4.8 5.8 6.7 7.7 8.6 9.6 11.5 13.4 15.4
90 198 4.3 5.4 6.5 7.6 8.6 9.7 10.8 13 15.1 17.3
100 220 4.8 6 7.2 8.4 9.6 10.8 12 14.4 16.8 19.2
* 500 mg ZEMURON in 100 mL solution.

Dosage in Specific Populations

Pediatric Patients

The recommended initial intubation dose of ZEMURON is 0.6 mg/kg; however, a lower dose of 0.45 mg/kg may be used depending on anesthetic technique and the age of the patient.

For sevoflurane (induction) ZEMURON doses of 0.45 mg/kg and 0.6 mg/kg in general produce excellent to good intubating conditions within 75 seconds. When halothane is used, a 0.6 mg/kg dose of ZEMURON resulted in excellent to good intubating conditions within 60 seconds.

The time to maximum block for an intubating dose was shortest in infants (28 days up to 3 months) and longest in neonates (birth to less than 28 days). The duration of clinical relaxation following an intubating dose is shortest in children (greater than 2 years up to 11 years) and longest in infants.

When sevoflurane is used for induction and isoflurane/nitrous oxide for maintenance of general anesthesia, maintenance dosing of ZEMURON can be administered as bolus doses of 0.15 mg/kg at reappearance of T3 in all pediatric age groups. Maintenance dosing can also be administered at the reappearance of T2 at a rate of 7 to 10 mcg/kg/min, with the lowest dose requirement for neonates (birth to less than 28 days) and the highest dose requirement for children (greater than 2 years up to 11 years).

When halothane is used for general anesthesia, patients ranging from 3 months old through adolescence can be administered ZEMURON maintenance doses of 0.075 to 0.125 mg/kg upon return of T1 to 0.25% to provide clinical relaxation for 7 to 10 minutes. Alternatively, a continuous infusion of ZEMURON initiated at a rate of 12 mcg/kg/min upon return of T1 to 10% (one twitch present in train-offour) may also be used to maintain neuromuscular blockade in pediatric patients.

Additional information for administration to pediatric patients of all age groups is presented elsewhere in the label [see CLINICAL PHARMACOLOGY].

The infusion of ZEMURON must be individualized for each patient. The rate of administration should be adjusted according to the patient's twitch response as monitored with the use of a peripheral nerve stimulator. Spontaneous recovery and reversal of neuromuscular blockade following discontinuation of ZEMURON infusion may be expected to proceed at rates comparable to that following similar total exposure to single bolus doses [see CLINICAL PHARMACOLOGY].

ZEMURON is not recommended for rapid sequence intubation in pediatric patients.

Geriatric Patients

Geriatric patients (65 years or older) exhibited a slightly prolonged median (range) clinical duration of 46 (22-73), 62 (49-75), and 94 (64-138) minutes under opioid/nitrous oxide/oxygen anesthesia following doses of 0.6, 0.9, and 1.2 mg/kg, respectively. No differences in duration of neuromuscular blockade following maintenance doses of ZEMURON were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see CLINICAL PHARMACOLOGY ].

Patients with Renal or Hepatic Impairment

No differences from patients with normal hepatic and kidney function were observed for onset time at a dose of 0.6 mg/kg ZEMURON. When compared to patients with normal renal and hepatic function, the mean clinical duration is similar in patients with endstage renal disease undergoing renal transplant, and is about 1.5 times longer in patients with hepatic disease. Patients with renal failure may have a greater variation in duration of effect [see Use in Specific Populations and CLINICAL PHARMACOLOGY].

Obese Patients

In obese patients, the initial dose of ZEMURON 0.6 mg/kg should be based upon the patient's actual body weight [see Clinical Studies].

An analysis across all US controlled clinical studies indicates that the pharmacodynamics of ZEMURON are not different between obese and nonobese patients when dosed based upon their actual body weight.

Patients with Reduced Plasma Cholinesterase Activity

Rocuronium metabolism does not depend on plasma cholinesterase so dosing adjustments are not needed in patients with reduced plasma cholinesterase activity.

Patients with Prolonged Circulation Time

Because higher doses of ZEMURON produce a longer duration of action, the initial dosage should usually not be increased in these patients to reduce onset time; instead, in these situations, when feasible, more time should be allowed for the drug to achieve onset of effect [see WARNINGS AND PRECAUTIONS].

Patients with Drugs or Conditions Causing Potentiation of Neuromuscular Block

The neuromuscular blocking action of ZEMURON is potentiated by isoflurane and enflurane anesthesia. Potentiation is minimal when administration of the recommended dose of ZEMURON occurs prior to the administration of these potent inhalation agents. The median clinical duration of a dose of 0.57 to 0.85 mg/kg was 34, 38, and 42 minutes under opioid/nitrous oxide/oxygen, enflurane and isoflurane maintenance anesthesia, respectively. During 1 to 2 hours of infusion, the infusion rate of ZEMURON required to maintain about 95% block was decreased by as much as 40% under enflurane and isoflurane anesthesia [see DRUG INTERACTIONS].

Preparation for Administration of ZEMURON

Diluent Compatibility

ZEMURON is compatible in solution with:

0.9% NaCI solution sterile water for injection
5% glucose in water lactated Ringers
5% glucose in saline  

ZEMURON is compatible in the above solutions at concentrations up to 5 mg/mL for 24 hours at room temperature in plastic bags, glass bottles, and plastic syringe pumps.

Drug Admixture Incompatibility

ZEMURON is physically incompatible when mixed with the following drugs:

amphotericin hydrocortisone sodium succinate
amoxicillin insulin
azathioprine Intralipid
cefazolin ketorolac
cloxacillin lorazepam
dexamethasone methohexital
diazepam methylprednisolone
erythromycin thiopental
famotidine trimethoprim
furosemide vancomycin

If ZEMURON is administered via the same infusion line that is also used for other drugs, it is important that this infusion line is adequately flushed between administration of ZEMURON and drugs for which incompatibility with ZEMURON has been demonstrated or for which compatibility with ZEMURON has not been established.

Infusion solutions should be used within 24 hours of mixing. Unused portions of infusion solutions should be discarded.

ZEMURON should not be mixed with alkaline solutions [see WARNINGS AND PRECAUTIONS].

Visual Inspection

Parenteral drug products should be inspected visually for particulate matter and clarity prior to administration whenever solution and container permit. Do not use solution if particulate matter is present.

HOW SUPPLIED

Dosage Forms And Strengths

ZEMURON (rocuronium bromide) injection is available as

  • 5 mL multiple dose vials containing 50 mg rocuronium bromide injection (10 mg/mL)
  • 10 mL multiple dose vials containing 100 mg rocuronium bromide injection (10 mg/mL)

Storage And Handling

ZEMURON (rocuronium bromide) injection is available in the following:

  • ZEMURON 5 mL multiple dose vials containing 50 mg rocuronium bromide injection (10 mg/mL)

Box of 10 NDC 0052-0450-15

  • ZEMURON 10 mL multiple dose vials containing 100 mg rocuronium bromide injection (10 mg/mL)

Box of 10 NDC 0052-0450-16

The packaging of this product contains no natural rubber (latex).

ZEMURON should be stored in a refrigerator, 2-8°C (36-46°F). DO NOT FREEZE. Upon removal from refrigeration to room temperature storage conditions (25°C/77°F), use ZEMURON within 60 days. Use opened vials of ZEMURON within 30 days.

Safety and Handling

There is no specific work exposure limit for ZEMURON. In case of eye contact, flush with water for at least 10 minutes.

Manuf. for: merck sharp & Dohme Corp., a subsidiary of MERCK & CO., INC., Whitehouse Station, NJ 08889, USA. Manufactured by: Organon (Ireland) Ltd., Swords, Co. Dublin, Ireland, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Revised: 09/2012

Last reviewed on RxList: 6/7/2013
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.